Skip to main content
Erschienen in: Clinical Research in Cardiology 2/2024

27.06.2023 | Original Paper

Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination

verfasst von: Pablo Pastor Pueyo, Elena Gambó Ruberte, Jara Gayán Ordás, Lucía Matute Blanco, Domingo Pascual Figal, José María Larrañaga Moreira, José Javier Gómez Barrado, David González Calle, Luis Almenar Bonet, Gonzalo Luis Alonso Salinas, Miguel José Corbí Pascual, María Plaza Martín, Jaume Pons Llinares, Alejandro Durante López, Manuel Barreiro Pérez, Fernando Candanedo Ocaña, Javier Bautista García, Germán Merchán Ortega, Fernando Domínguez Rodríguez, Virgilio Martínez Mateo, Marta Campreciós Crespo, Martín Quintás Guzmán, Laura Jordán Martínez, Jaime Aboal Viñas, Judit Rodríguez López, Sara Fernández Santos, Pablo Revilla Martí, Laura Álvarez Roy, Juan Carlos Gómez Polo, José Manuel García Pinilla, María Ferré Vallverdú, Lourdes García Bueno, Toni Soriano Colomé, Fernando Worner Diz

Erschienen in: Clinical Research in Cardiology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction and objectives

Vaccines against SARS-CoV-2 have been a major scientific and medical achievement in the control of the COVID-19 pandemic. However, very infrequent cases of inflammatory heart disease have been described as adverse events, leading to uncertainty in the scientific community and in the general population.

Methods

The Vaccine–Carditis Registry has included all cases of myocarditis and pericarditis diagnosed within 30 days after COVID-19 vaccination since August 1, 2021 in 29 centers throughout the Spanish territory. The definitions of myocarditis (probable or confirmed) and pericarditis followed the consensus of the Centers for Disease Control and the Clinical Practice Guidelines of the European Society of Cardiology. A comprehensive analysis of clinical characteristics and 3-month evolution is presented.

Results

From August 1, 2021, to March 10, 2022, 139 cases of myocarditis or pericarditis were recorded (81.3% male, median age 28 years). Most cases were detected in the 1st week after administration of an mRNA vaccine, the majority after the second dose. The most common presentation was mixed inflammatory disease (myocarditis and pericarditis). 11% had left ventricular systolic dysfunction, 4% had right ventricular systolic dysfunction, and 21% had pericardial effusion. In cardiac magnetic resonance studies, left ventricular inferolateral involvement was the most frequent pattern (58%). More than 90% of cases had a benign clinical course. After a 3-month follow-up, the incidence of adverse events was 12.78% (1.44% mortality).

Conclusions

In our setting, inflammatory heart disease after vaccination against SARS-CoV-2 predominantly affects young men in the 1st week after the second dose of RNA-m vaccine and presents a favorable clinical course in most cases.

Graphical abstract

Literatur
7.
Zurück zum Zitat U.S. Food and Drug Administration (FDA) (2021) Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) U.S. Food and Drug Administration (FDA) (2021) Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)
8.
Zurück zum Zitat U.S. Food and Drug Administration (FDA) (2021) Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19) U.S. Food and Drug Administration (FDA) (2021) Fact sheet for healthcare providers administering vaccine (vaccination providers) emergency use Authorization (EUA) of the Moderna COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19)
9.
Zurück zum Zitat Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical Trial Group et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615CrossRefPubMed Polack FP, Thomas SJ, Kitchin N, C4591001 Clinical Trial Group et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603–2615CrossRefPubMed
10.
Zurück zum Zitat Baden LR, El Sahly HM, Essink B, COVE Study Group et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403–416CrossRefPubMed Baden LR, El Sahly HM, Essink B, COVE Study Group et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403–416CrossRefPubMed
11.
Zurück zum Zitat Sadoff J, Gray G, Vandebosch A, ENSEMBLE Study Group et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–2201CrossRefPubMed Sadoff J, Gray G, Vandebosch A, ENSEMBLE Study Group et al (2021) Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med 384(23):2187–2201CrossRefPubMed
12.
Zurück zum Zitat Falsey AR, Sobieszczyk ME, Hirsch I, AstraZeneca AZD1222 Clinical Study Group et al (2021) Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med 385(25):2348–2360CrossRefPubMed Falsey AR, Sobieszczyk ME, Hirsch I, AstraZeneca AZD1222 Clinical Study Group et al (2021) Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine. N Engl J Med 385(25):2348–2360CrossRefPubMed
16.
Zurück zum Zitat Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19. Agencia Española del Medicamentos y Productos Sanitarios. 9 Dic 2021. Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19 - Agencia Española de Medicamentos y Productos Sanitarios (aemps.gob.es) Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19. Agencia Española del Medicamentos y Productos Sanitarios. 9 Dic 2021. Actualización sobre el riesgo de miocarditis y pericarditis con las vacunas de ARNm frente a la COVID-19 - Agencia Española de Medicamentos y Productos Sanitarios (aemps.gob.es)
17.
Zurück zum Zitat Mevorach D et al (2021) Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 385(23):2140–2149CrossRefPubMed Mevorach D et al (2021) Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med 385(23):2140–2149CrossRefPubMed
18.
Zurück zum Zitat Hause AM et al (2021) COVID-19 vaccine safety in adolescents aged 12–17 Years—United States, December 14, 2020–July 16, 2021. MMWR Morb Mortal Wkly Rep 70(31):1053–1058CrossRefPubMedPubMedCentral Hause AM et al (2021) COVID-19 vaccine safety in adolescents aged 12–17 Years—United States, December 14, 2020–July 16, 2021. MMWR Morb Mortal Wkly Rep 70(31):1053–1058CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Oster ME et al (2022) Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US From December 2020 to August 2021. JAMA 327:331–340CrossRefPubMedPubMedCentral Oster ME et al (2022) Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US From December 2020 to August 2021. JAMA 327:331–340CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132–2139CrossRefPubMed Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD, Kornowski R (2021) Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med 385(23):2132–2139CrossRefPubMed
22.
Zurück zum Zitat Le Vu S, Bertrand M, Jabagi MJ et al (2022) Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 13:3633ADSCrossRefPubMedPubMedCentral Le Vu S, Bertrand M, Jabagi MJ et al (2022) Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines. Nat Commun 13:3633ADSCrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Lane S, Yeomans A, Shakir S (2022) Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open 12(5):e059223CrossRefPubMed Lane S, Yeomans A, Shakir S (2022) Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. BMJ Open 12(5):e059223CrossRefPubMed
25.
Zurück zum Zitat Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1(1):3–14PubMed Aretz HT, Billingham ME, Edwards WD, Factor SM, Fallon JT, Fenoglio JJ Jr, Olsen EG, Schoen FJ (1987) Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1(1):3–14PubMed
26.
Zurück zum Zitat Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72(24):3158–3176CrossRefPubMed Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72(24):3158–3176CrossRefPubMed
27.
Zurück zum Zitat Adler Y, Charron P, Imazio M, ESC Scientific Document Group et al (2015) 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC). Eur Heart J 36(42):2921–2964CrossRefPubMed Adler Y, Charron P, Imazio M, ESC Scientific Document Group et al (2015) 2015 ESC guidelines for the diagnosis and management of pericardial diseases: the task force for the diagnosis and management of pericardial diseases of the European Society of Cardiology (ESC). Eur Heart J 36(42):2921–2964CrossRefPubMed
28.
Zurück zum Zitat Kini A, Cao D, Nardin M et al (2021) Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur Heart J Qual Care Clin Outcomes 7(5):438–446CrossRefPubMed Kini A, Cao D, Nardin M et al (2021) Types of myocardial injury and mid-term outcomes in patients with COVID-19. Eur Heart J Qual Care Clin Outcomes 7(5):438–446CrossRefPubMed
29.
Zurück zum Zitat Heymans S, Cooper LT (2022) Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol 19(2):75–77CrossRefPubMed Heymans S, Cooper LT (2022) Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms. Nat Rev Cardiol 19(2):75–77CrossRefPubMed
30.
Zurück zum Zitat Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L (2022) Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ 378:e069445CrossRefPubMed Pillay J, Gaudet L, Wingert A, Bialy L, Mackie AS, Paterson DI, Hartling L (2022) Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ 378:e069445CrossRefPubMed
31.
Zurück zum Zitat Thurner L, Kessel C, Fadle N et al (2022) IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N Engl J Med 387(16):1524–1527CrossRefPubMed Thurner L, Kessel C, Fadle N et al (2022) IL-1RA antibodies in myocarditis after SARS-CoV-2 vaccination. N Engl J Med 387(16):1524–1527CrossRefPubMed
32.
Zurück zum Zitat Aquaro GD, Perfetti M, Camastra G, Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology et al (2017) Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol. 70(16):1977–1987CrossRefPubMed Aquaro GD, Perfetti M, Camastra G, Cardiac Magnetic Resonance Working Group of the Italian Society of Cardiology et al (2017) Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. J Am Coll Cardiol. 70(16):1977–1987CrossRefPubMed
33.
Zurück zum Zitat Lai FTT, Chan EWW, Huang L et al (2022) Prognosis of myocarditis developing after mRNA COVID-19 vaccination compared with viral myocarditis. J Am Coll Cardiol 80(24):2255–2265CrossRefPubMedPubMedCentral Lai FTT, Chan EWW, Huang L et al (2022) Prognosis of myocarditis developing after mRNA COVID-19 vaccination compared with viral myocarditis. J Am Coll Cardiol 80(24):2255–2265CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Fairweather D, Cooper LT Jr, Blauwet LA (2013) Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 38:7–46CrossRefPubMedPubMedCentral Fairweather D, Cooper LT Jr, Blauwet LA (2013) Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol 38:7–46CrossRefPubMedPubMedCentral
Metadaten
Titel
Vaccine–carditis study: Spanish multicenter registry of inflammatory heart disease after COVID-19 vaccination
verfasst von
Pablo Pastor Pueyo
Elena Gambó Ruberte
Jara Gayán Ordás
Lucía Matute Blanco
Domingo Pascual Figal
José María Larrañaga Moreira
José Javier Gómez Barrado
David González Calle
Luis Almenar Bonet
Gonzalo Luis Alonso Salinas
Miguel José Corbí Pascual
María Plaza Martín
Jaume Pons Llinares
Alejandro Durante López
Manuel Barreiro Pérez
Fernando Candanedo Ocaña
Javier Bautista García
Germán Merchán Ortega
Fernando Domínguez Rodríguez
Virgilio Martínez Mateo
Marta Campreciós Crespo
Martín Quintás Guzmán
Laura Jordán Martínez
Jaime Aboal Viñas
Judit Rodríguez López
Sara Fernández Santos
Pablo Revilla Martí
Laura Álvarez Roy
Juan Carlos Gómez Polo
José Manuel García Pinilla
María Ferré Vallverdú
Lourdes García Bueno
Toni Soriano Colomé
Fernando Worner Diz
Publikationsdatum
27.06.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Clinical Research in Cardiology / Ausgabe 2/2024
Print ISSN: 1861-0684
Elektronische ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-023-02225-0

Weitere Artikel der Ausgabe 2/2024

Clinical Research in Cardiology 2/2024 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.